Last reviewed · How we verify
AD-2022
AD-2022 is a small molecule that targets the PI3K/AKT pathway.
AD-2022 is a small molecule that targets the PI3K/AKT pathway. Used for Metastatic triple-negative breast cancer.
At a glance
| Generic name | AD-2022 |
|---|---|
| Sponsor | Addpharma Inc. |
| Drug class | PI3K inhibitor |
| Target | PI3K |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
AD-2022 works by inhibiting the PI3K/AKT pathway, which is involved in cell proliferation and survival. This inhibition leads to the reduction of tumor growth and metastasis. The exact molecular mechanism is still being studied.
Approved indications
- Metastatic triple-negative breast cancer
Common side effects
- Diarrhea
- Fatigue
- Nausea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AD-2022 CI brief — competitive landscape report
- AD-2022 updates RSS · CI watch RSS
- Addpharma Inc. portfolio CI